Placebo-controlled, randomized, phase II study of radium-223 in metastatic hormone refractory prostate cancer (HRPC)

被引：0

作者：

Nilsson, S. ^{[1
]}

Franzen, L. ^{[2
]}

Tyrrel, C. ^{[3
]}

Blom, R. ^{[4
]}

Tennvall, J. ^{[5
]}

Lennernas, B. ^{[6
]}

Johannessen, D. C. ^{[7
]}

Sokal, M. ^{[8
]}

Parker, C. ^{[9
]}

Bruland, O. S. ^{[10
]}

机构：

[1] Karolinska Hosp & Inst, Radiumhemmet, Stockholm, Sweden

[2] Lanssjukhuset Sundsvall Harnosand, Sundsvall, Sweden

[3] Plymouth Gen Hosp, Plymouth, Devon, England

[4] Linkoping Univ Hosp, Linkoping, Sweden

[5] Univ Lund Hosp, Lund, Sweden

[6] Sahlgrens Univ Hosp, Gothenburg, Sweden

[7] Haukeland Hosp, Bergen, Norway

[8] City Hosp Nottingham, Nottingham, England

[9] Royal Marsden Hosp, Sutton, Surrey, England

[10] Norwegian Radium Hosp, Oslo, Norway

来源：

EJC SUPPLEMENTS | 2007年 / 5卷 / 04期

关键词：

D O I：

10.1016/S1359-6349(07)71121-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4054

引用

页码：295 / 295

页数：1

共 2 条

[1] High-linear energy transfer irradiation targeted to skeletal metastases by the α-emitter 223Ra:: Adjuvant or alternative to conventional modalities? [J].

Bruland, Oyvind S. ;

Nilsson, Sten ;

Fisher, Darrell R. ;

Larsen, Roy H. .

CLINICAL CANCER RESEARCH, 2006, 12 (20) :6250S-6257S

[2] First clinical experience with α-emitting radium-223 in the treatment of skeletal metastases [J].

Nilsson, S ;

Larsen, RH ;

Fosså, SD ;

Balteskard, L ;

Borch, KW ;

Westlin, JE ;

Salberg, G ;

Bruland, OS .

CLINICAL CANCER RESEARCH, 2005, 11 (12) :4451-4459

← 1 →